KEGG   DRUG: Daclizumab
Entry
D03639                      Drug                                   
Name
Daclizumab (USAN/INN);
Zenapax (TN);
Zinbryta (TN)
Formula
C6394H9888N1696O2012S44
Exact mass
144031.1268
Mol weight
144119.9425
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT SYRMHWVRQA PGQGLEWIGY INPSTGYTEY
NQKFKDKATI TADESTNTAY MELSSLRSED TAVYYCARGG GVFDYWGQGT LVTVSSASTK
GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS
LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF
LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSRDELTKN
QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN
VFSCSVMHEA LHNHYTQKSL SLSPGK
(Light chain)
DIQMTQSPST LSASVGDRVT ITCSASSSIS YMHWYQQKPG KAPKLLIYTT SNLASGVPAR
FSGSGSGTEF TLTISSLQPD DFATYYCHQR STYPLTFGQG TKVEVKRTVA APSVFIFPPS
DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
(Disulfide bridge: H22-H96, H143-H199, H260-H320, H366-H424, H225-H'225, H228-H'228, L23-L87, L133-L193, H219-L213)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Remark
ATC code: L04AC01
Efficacy
Immunosuppressant, Anti-CD25 antibody
  Disease
Multiple sclerosis [DS:H01490]
  Type
Monoclonal antibody
Target
IL2RA (CD25) [HSA:3559] [KO:K05068]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04144  Endocytosis
hsa04630  JAK-STAT signaling pathway
hsa04640  Hematopoietic cell lineage
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC01 Daclizumab
      D03639  Daclizumab (USAN/INN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D03639  Daclizumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL2RA (CD25)
     D03639  Daclizumab (USAN/INN)
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D03639
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D03639
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D03639
Other DBs
CAS: 152923-56-3
PubChem: 17397742

» Japanese version   » Back

  All links  
Ontology (6)   
   KEGG BRITE (6)   
Disease (1)   
   KEGG DISEASE (1)   
Drug (1)   
   KEGG DGROUP (1)   
Chemical substance (1)   
   PubChem (1)   
Gene (2)   
   KEGG ORTHOLOGY (1)   
   KEGG GENES (1)   
All databases (11)   

Download RDF
DBGET integrated database retrieval system